Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
502 participants
INTERVENTIONAL
2024-02-15
2025-04-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension
NCT06671392
A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B
NCT06884085
Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension
NCT06682000
Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension
NCT02322450
Management of Hypertension and Multiple Risk Factors to Enhance Cardiovascular Health
NCT02330224
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test group
AD-223A+AD-223B+AD-223C Placebo
AD-223A
PO, Once daily(QD), 8weeks
AD-223B
PO, Once daily(QD), 8weeks
AD-223C Placebo
PO, Once daily(QD), 8weeks
Control group 1
AD-223A+AD-223B Placebo+AD-223C Placebo
AD-223A
PO, Once daily(QD), 8weeks
AD-223B Placebo
PO, Once daily(QD), 8weeks
AD-223C Placebo
PO, Once daily(QD), 8weeks
Control group 2
AD-223A Placebo+AD-223B+AD-223C Placebo
AD-223B
PO, Once daily(QD), 8weeks
AD-223A Placebo
PO, Once daily(QD), 8weeks
AD-223C Placebo
PO, Once daily(QD), 8weeks
Control group 3
AD-223A Placebo+AD-223B Placebo+AD-223C
AD-223C
PO, Once daily(QD), 8weeks
AD-223A Placebo
PO, Once daily(QD), 8weeks
AD-223B Placebo
PO, Once daily(QD), 8weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AD-223A
PO, Once daily(QD), 8weeks
AD-223B
PO, Once daily(QD), 8weeks
AD-223C
PO, Once daily(QD), 8weeks
AD-223A Placebo
PO, Once daily(QD), 8weeks
AD-223B Placebo
PO, Once daily(QD), 8weeks
AD-223C Placebo
PO, Once daily(QD), 8weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Other inclusions applied
Exclusion Criteria
* Other exclusions applied
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Addpharma Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jin Ho Shin, M.D., Ph.D
Role: PRINCIPAL_INVESTIGATOR
Hanyang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hanyang University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AD-223P3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.